Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Professional Education
- Residency: Universite Laval (1987) Canada
- Internship: Universite Laval (1984) Canada
- Medical Education: Universite Laval (1983) Canada
- Fellowship: University of British Columbia Radiology Residency (1990) Canada
- Fellowship: McMaster University Michael G DeGroote School of Medicine Registrar (1991) Canada
- Board Certification: Royal College of Physicians and Surgeons of Canada, Medical Oncology (1990)
- Board Certification: Royal College of Physicians and Surgeons, Hematology (1989)
- Board Certification: Royal College of Physicians and Surgeons of Canada, Internal Medicine (1988)
- Oncology, University of BC, Canada, Medical Oncology (1990)
- Board certification, Hematology, Canadian Hematology Board (1989)
- Fellowship: University of Montreal (1989) Canada
- Hematology, University of Montreal, Canada, Hematology (1989)
- F.R.C.P.(C), Internal Medicine, Canadian Board (1987)
- M.D., Laval University, Canada, Medicine (1984)
Administrative Appointments
- Medical Director, Oral Anticoagulation Clinic, Stanford Hospital and Clinics (2004 - Present)
Publications
-
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., … Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865–70. -
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
Sagrieya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., Hamilton, A., & Altman, R. B. (2010). Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. PHARMACOGENETICS AND GENOMICS, 20(7), 407–13. -
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81. -
Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer
Lee, R., Wen, A., & Berube, C. (2011). Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 68(9), 814–17. -
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37. -
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901. -
Accessory splenules in autoimmune hemolytic anemia.
Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. American Journal of Hematology, 88(2), 156-? -
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441–45. -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15. -
Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome
Zikos, T. A., Sokolove, J., Ahuja, N., & Berube, C. (2015). Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 21(6), 311–13. -
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59. -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. LEUKEMIA & LYMPHOMA, 57(3), 609–15. -
Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting.
Mou, E., Kwang, H., Hom, J., Shieh, L., Kumar, A., Richman, I., & Berube, C. (2017). Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting. Journal of Hospital Medicine, 12(9), 735–38. -
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. -
Prochemerin cleavage by factor XIa links coagulation and inflammation
Ge, X., Yamaguchi, Y., Zhao, L., Bury, L., Gresele, P., Berube, C., … Morser, J. (2018). Prochemerin cleavage by factor XIa links coagulation and inflammation. BLOOD, 131(3), 353–64. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21). -
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology. -
Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Zikos, T. A., Triadafilopoulos, G., Berube, C., & Regalia, K. A. (2018). Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Digestive Diseases and Sciences. -
An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting.
Jun, T., Kwang, H., Mou, E., Berube, C., Bentley, J., Shieh, L., & Hom, J. (2018). An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting. Journal of General Internal Medicine. -
Thrombophilia testing in the inpatient setting: impact of an educational intervention.
Kwang, H., Mou, E., Richman, I., Kumar, A., Berube, C., Kaimal, R., … Hom, J. (2019). Thrombophilia testing in the inpatient setting: impact of an educational intervention. BMC Medical Informatics and Decision Making, 19(1), 167. -
Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6. -
Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients.
Jin, M. C., Sussman, E. S., Feng, A. Y., Han, S. S., Skirboll, S. L., Berube, C., & Ratliff, J. K. (2021). Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients. Thrombosis Research, 204, 126–133.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia »
- Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma »
- Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion »
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy »
- Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia »
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia »
- COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial »
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia »
Practice Locations
Anticoagulation Clinic Palo Alto, CA
Palo Alto, CA
Anticoagulation Clinic
900 Blake Wilbur Drive, 2nd Floor, Room W2081
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Hematologic Cancer Program Palo Alto, CA
Palo Alto, CA
Hematologic Cancer Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(46 reviews)
Very good.
Very clear, helpful, kind listeners, informative.
Dr. Berube as always is outstanding. Her fellow was excellent also.
She is outstanding! Excellent!
Dr. Berube made my daughter and I very comfortable. Very easy to understand. Called me by 6:00 PM the following evening with reports.
I really felt like Dr. Berube and her assistant spent a good long time talking with me. I appreciate their care and concern.
Dr. Berube and her fellow were very thorough in their explanations.
Great dr. was disappointed I was unable to have all tests she needed. After visit, I got a clot in my leg & had another minor stroke from traveling. ER's don't do much only observe - It would take 2 wks. to get insurance approval - so I can't prove it. My dr. here knows about it.
Dr. Berube is an excellent, quality caring dr., whether I was in the hospital for my dr. rounds or for follow ups. She motivates & encourages you to stay positive. 8. Quality time, not rushed.
Dr. Berube was very friendly and told me all felt my problem (chronic fatigue) was not linked to a blood disorder. However - I was essentially told to wait and get some rest before continuing any treatment options. I felt extremely dismissed and not taken seriously at all. I could tell she did not believe me.
Dr. Berube is great. She showed empathy and took her time to answer my questions.
Dr. Berube is excellent. I trust her
Dr. Berube was excellent and worth our travel time from Chico to see her (3 hours & hotel room).
I would recommend all the world.
Dr. Berube had a vast knowledge re: my specific bleeding disorder.
I could not ask for a more competent and compassionate physician. Dr. Berube.
Dr Berube is always above and beyond when it comes to standard of care. One of the best experiences I have ever had at a hemo clinic.
Dr. Berube is a wonderful doctor.
Dr. Berube is a brilliant angel!
Very polite, sweet, and compassionate. Showed general concern for complications I was having that day.
My doctor... she was amazing in every aspect.
Dr. Berube and her staff were very nice- very helpful.
Both Dr. Berube and the resident were very informed and helped me come up with a good care plan.
The providers, Dr's, nurses, PA's etc are substantially better than the facility clinic than I usually attend. It is a night and day comparison.
Dr. Berube was excellent. Answered all of my questions thoroughly, really took the time to explain my condition in a way I understood.
Dr. Berube ALWAYS greets me with a smile and takes excellent care of me!
Love Dr. Berube.
Both doctors took all the time I needed an were clearly concerned to help resolve the worries of my wife and I.
Good.
Very thorough.
Dr. Berube is amazing!
Dr. Berube was excellent in every way -
Everything was good.
Dr. Berube has always made me feel incredibly comfortable to share any concern or question.
I had many questions & concerns during my visit. Dr. Berube took a lot of time with me & did not rush me.
Excellent!
I have seen many hematologists, and none compare to Dr. Berube. She's great!
Dr. Caroline Berube even her telling me about my weight, give me the power and I will not let her down.
You need a spot here for EXCELLENT because to call Dr. Berube' "very good" is negligent - she saved my life from AML and I am forever in her debt.
Dr. Berube has big a huge part of my recovery.
Dr. Berube went above & beyond to help me get the medication I needed & even personally called the insurance company to help make sure it was covered.
Dr. Berube has the patience of a saint. Very cautious and concerned. ALWAYS answers my endless list of questions. Worked hard to get me into NIH trial!
Dr. Berube is wonderful physician, kind, thoughtful, helpful.
If anyone I know needed this type of doctor I would INSIST that they see Dr. Berube.
Doctor Berube was all business not very personable at all nor very friendly. Her assistant was much more friendly and seemed more concerned about my health then her.
Dr. Berube is an exceptional care provider.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
- Send referrals online
- View referral status
- Access medical records